Mirna Therapeutics Inc (NASDAQ:MIRN)‘s stock had its “neutral” rating restated by Leerink Swann in a report released on Wednesday.

The analysts wrote, “We maintain our Market Perform rating for Amgen along with our $193 price target.””

MIRN has been the subject of several other research reports. Zacks Investment Research upgraded shares of Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Thursday, July 14th. HC Wainwright initiated coverage on shares of Mirna Therapeutics in a research report on Monday, September 12th. They set a “buy” rating and a $6.00 price target for the company. Cantor Fitzgerald lowered shares of Mirna Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Oppenheimer Holdings Inc. lowered shares of Mirna Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Finally, Citigroup Inc. lowered shares of Mirna Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $7.00 to $4.50 in a research report on Tuesday, August 16th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Mirna Therapeutics currently has a consensus rating of “Hold” and an average price target of $7.38.

Analyst Recommendations for Mirna Therapeutics (NASDAQ:MIRN)

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/mirna-therapeutics-inc-mirn-receives-neutral-rating-from-leerink-swann.html

Mirna Therapeutics (NASDAQ:MIRN) traded down 23.58% during trading on Wednesday, reaching $1.88. 155,179 shares of the company’s stock traded hands. The firm has a 50 day moving average of $3.17 and a 200 day moving average of $4.12. Mirna Therapeutics has a 1-year low of $1.82 and a 1-year high of $11.01. The firm’s market capitalization is $39.17 million.

About Mirna Therapeutics

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

5 Day Chart for NASDAQ:MIRN

Receive News & Ratings for Mirna Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.